The rise of Sildenafil initially fueled a boom for pharma, but recent changes present a complicated scenario for shareholders. Generic versions are eating into revenue, and ongoing patent challenges add additional https://amieijcr262634.pages10.com/sildenafil-and-the-pharmaceutical-industry-a-volatile-investment-76596859